RecruitingPhase 3NCT07489131

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

Studying Medullary sponge kidney

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alvotech Swiss AG
Intervention
AVT29 (proposed aflibercept HD biosimilar)(drug)
Enrollment
256 target
Eligibility
18 years · All sexes
Timeline
20262028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07489131 on ClinicalTrials.gov

Other trials for Medullary sponge kidney

Additional recruiting or active studies for the same condition.

See all trials for Medullary sponge kidney

← Back to all trials